{"id":"W1969175190","doi":"10.1073/pnas.1220763110","title":"Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR","year":2013,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; University of Alberta; Università degli Studi di Milano; European Commission; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Israel Cancer Research Fund","keywords":"Cetuximab; Epidermal growth factor receptor; Panitumumab; Monoclonal antibody; Triple-negative breast cancer; Cancer research; Antibody; EGFR inhibitors; Growth inhibition; Epidermal growth factor; Receptor; Chemistry; Breast cancer; Cell growth; Biology; Medicine; Cancer; Immunology; Internal medicine; Biochemistry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008455791,0.00008210501,0.0002459866,0.0002953925,0.00008897075,0.000009698048,0.0003430753,0.00006680322,0.00008688887],"category_scores_gemma":[0.0005189907,0.00005598384,0.00006705118,0.00117894,0.001111935,0.0005077203,0.0001163336,0.0001499509,0.000001363266],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009340222,"about_ca_system_score_gemma":0.0001355969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003794116,"about_ca_topic_score_gemma":4.970535e-7,"domain_scores_codex":[0.9975167,0.000008404584,0.0004191737,0.0001906767,0.001711571,0.0001535084],"domain_scores_gemma":[0.9975886,0.0001181657,0.0003892257,0.000011681,0.001830386,0.00006192763],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00005169859,0.0002941142,0.01158298,0.000371331,0.00004205257,2.795203e-9,0.001167223,0.0001264326,0.9419759,0.0243613,0.01881053,0.001216455],"study_design_scores_gemma":[0.0006774777,0.0001484579,0.09986496,0.0007041994,0.00001955659,0.000004053157,0.0007348736,0.002765876,0.836128,0.05885286,0.00003004841,0.00006962421],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9708214,0.0001477291,0.00000458867,0.02044059,0.00001705962,0.0006764533,0.0002173827,0.000006566089,0.007668209],"genre_scores_gemma":[0.9982718,0.0001183703,0.000908939,0.0002177366,0.00002801074,0.00005842403,3.912529e-7,0.000004798423,0.0003915848],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1058479,"threshold_uncertainty_score":0.409697,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.073597400590453,"score_gpt":0.3849994061081312,"score_spread":0.3114020055176782,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}